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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.11.003PURPOSE: High interest in triple-negative breast cancers is not surprising as this category of patients benefits
neither from hormonal therapies nor from anti HER2 treatments. Blockade of angiogenesis by metronomic che-
motherapy as well as other antiangiogenics might improve outcomes in this group of patients. This study aims to
evaluate the tolerability and efficacy of metronomic capecitabine as extended adjuvant treatment for women
with triple-negative breast cancer.
METHODS: This is a prospective phase II study that included 41 patients diagnosed with triple-negative breast
cancer and who were indicated for adjuvant chemotherapy. They received capecitabine 500 mg PO twice daily
and continuously for six months after finishing six cycles of adjuvant FEC100 ± postoperative radiotherapy.
RESULTS: Forty-one patients were enrolled in this study between June 2010 and December 2013. Median age
was 50 years ranging from 27 to 67 years. Treatment was well tolerated. Adverse effects were grade 1 palmar–
plantar erythrodysesthesia in 13 patients (31.7%); grade 1 diarrhea in five patients (12.2%); and grade 1 vom-
iting in two patients (4.9%). Estimated median follow-up duration was 34 months. Estimated mean disease-free
survival (DFS) was 42.4 months (95% CI, 39.02–45.79), while median DFS was not reached. Estimated mean
overall survival was 44.34 months (95% CI 41.9–46.9).
CONCLUSION: Extended adjuvant metronomic capecitabine is well tolerated with patient compliance. These
results need to be compared in a study with control arm, larger sample, as well as longer follow-up.
KEYWORDS: Triple-negative breast cancer; Metronomic chemotherapy; Capecitabine; Extended adjuvant treatmentBreast cancer is the most common cancer inwomen worldwide and is one of the most com-mon cancers overall, in both developed and
developing countries.1
In Egypt, breast carcinoma constitutes 33% of all
female cancers according to ﬁgures from the Egyptian
National Cancer Institute.2
Breast cancer is divided into three major subtypes
based on the pattern of expression of hormone recep-
tors and HER2: luminal tumors (or HR positive),
HER2 ampliﬁed tumors, and the remaining subtypes
being collectively referred to as triple-negative breast
cancer (TNBC).3TNBC accounts for approximately 10–15% of
breast cancer cases. Generally, TNBC occurs in youn-
ger women and is marked by high rates of relapse, vis-
ceral and central nervous system (CNS) metastasis.
Patients with TNBC do not beneﬁt from established
targeted drugs with endocrine therapy or trastuzumab.4
Cytotoxic chemotherapy is still the mainstay of
treatment for TNBC despite the promise of new tar-
geted and biologic agents. Many studies have shown
signiﬁcant beneﬁt of chemotherapy in the neoadju-
vant, adjuvant, and metastatic treatment of TNBC.5
Capecitabine has limited reported data in TNBC,
but some reports suggest differential activity inarter 2015
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TNBC when compared with hormone receptor-posi-
tive breast cancer.5
Highly proliferative tumors, such as TNBC, have
enhanced angiogenesis that supports rapid growth
and early metastasis, and are found to have high levels
of vascular endothelial growth factor (VEGF). Drugs
developed to inhibit the angiogenic process may be
particularly effective in TNBC.6
Higher levels of VEGF in TNBC compared with
non-TNBC raises the question as to whether block-
ade of angiogenesis will improve outcome in this
group of patients. This is under current investigation
in adjuvant phase III trials evaluating the addition of
one year of maintenance therapy with metronomic
cyclophosphamide, methotrexate CM (International
Breast Cancer Study Group-22-00) as well as one
year of bevacizumab to standard chemotherapy (BEA-
TRICE Study).7
Metronomic chemotherapy refers to the chronic
administration of comparatively low doses of cyto-
toxic drugs at close, regular intervals with no pro-
longed drug-free interruptions. The advantage of
this strategy is lower toxicity and risk of emergence
of drug-resistant tumor cells than in conventional
administration.8AIM OF WORK
This study seeks to evaluate the tolerability and efﬁ-
cacy of metronomic capecitabine for six months as
extended adjuvant treatment for women with triple-
negative breast cancer.PATIENTS AND METHODS
This is a prospective phase II study that included 41
TNBC patients treated in Menoﬁa University Hospi-
tal, Egypt, and who were indicated for adjuvant che-
motherapy. They received capecitabine 500 mg PO
twice daily (every 12 h, and taken 30 min after meals)
for six months after completing six cycles of adjuvant
FEC100 and postoperative radiotherapy, where
indicated.ELIGIBILITY
Patients were required to be at least 18 years of age
and to have histopathologically operable proven breast
cancer. Primary tumor was conﬁrmed as triple-
negative; estrogen receptors and progesterone recep-
tors were negative by immunohistochemistry [IHC]
and HER2/neu was 0 or 1+ by IHC. DeﬁnitiveHematol Oncol Stem Cell Ther 8(1) First Quarter 2015loco-regional surgery was required to be completed
as primary treatment of breast cancer.
Patients were required to have World Health
Organization (WHO) performance status 0–1.
Further eligibility criteria included hemoglobin level
>10 g/dl, absolute neutrophil count >1500/ll, plate-
let count >100.000/ll, bilirubin < 1.5 upper normal
limit (UNL) aspartate aminotransferase (AST)/ala-
nine aminotransferase (ALT) < 2.5, creatinine < 1.5
UNL. All patients provided written informed consent
before study entry. Patients were ineligible if they
were over 75 years of age, with associated severe or
uncontrolled co-morbidity, or if they had a history
of another malignancy (except adequately treated
basal cell carcinoma of the skin or carcinoma in situ
of the cervix) or a history of hypersensitivity to cape-
citabine, ﬂuorouracil or dihydropyrimidine dehydro-
genase (DPD) deﬁciency.TREATMENT PLAN AND PATIENT
FOLLOW-UP
Before starting the study protocol, the patients under-
went full history-taking and physical examinations.
Baseline workup studies according to patient stage
(chest X-ray and abdomino-pelvic ultrasound in
stages I and II, and CT chest, abdomen and pelvis
and bone scan in stage III or in symptomatic
patients). Patients were followed up by interval his-
tory and physical examination every month during
administration of capecitabine, then every three
months for two years, and every six months
subsequently.
Mammography and breast ultrasound of the con-
tralateral breast (or both breasts if breast conserved)
were done every 12 months. CBC, liver and kidney
functions were checked monthly during administra-
tion of capecitabine.DRUG ADMINISTRATION
Patients received adjuvant chemotherapy FEC100
(ﬂuorouracil 500 mg/m2, cyclophosphamide
500 mg/m2 and epirubicin 100 mg/m2) followed by
postoperative radiotherapy if indicated, and then fol-
lowed by metronomic capecitabine 500 mg PO twice
daily (every 12 h, and taken 30 min after meals) for
six months.
Metronomic capecitabine was started after bone
marrow recovery from FEC, usually three weeks after
the last cycle. Time window between end of adjuvant
chemotherapy and the start of capecitabine must be23
Table 1. Patient and disease characteristics of the 41 eligible triple-
negative breast cancer patients who received metronomic capecitabine
as extended adjuvant chemotherapy for six months after adjuvant
24
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less than eight weeks. Toxicity was assessed according
to Common Terminology Criteria for Adverse Events
(CTCAE) v4.03.chemotherapy.
Variable Patient
no.
Percentage
Menopausal status Premenopausal 17 41.5
Postmenopausal 24 58.5
Side of the disease Right breast 22 53.7
Left breast 19 46.3STATISTICAL ANALYSIS
Data were analyzed using SPSS program for windows
version 16.0. Disease-free survival was estimated using
the Kaplan–Meier estimate. For categorical data we
used Chi-square test or Fisher’s exact test and for con-
tinuous data we used student t-test. Results were con-
sidered signiﬁcant at the 5% critical level (P < 0.05).Stage I 3 7.5
IIA 16 39
IIB 10 22
IIIA 9 24
IIIB 3 7.5
Grade G2 33 80.5
G3 8 19.5
LN capsular invasion Negative 36 87.8
Positive 5 12.2
Lymphovascular invasion Negative 39 95.1
Positive 2 4.9
Extensive intraductal
component
Negative 37 90.2
Positive 4 9.8
HER2/neu HER2/neu 0 33 80.5
HER2/neu + 1 8 19.5
Surgery MRM 29 70.7
CBS 12 29.3
Adjuvant radiotherapy Yes 27 75
No 9 25
Table 2. Toxicity profile of the 41 eligible triple-negative breast cancer
patients who received metronomic capecitabine as extended adjuvant
chemotherapy for six months after adjuvant chemotherapy.
Toxicity Grade Number of patients %
Hand & foot syndrome Grade I 13 31.7
Vomiting Grade I 5 12.2
Diarrhea Grade I 2 4.9RESULTS
Between June 2010 and December 2013, 41 patients
were enrolled and followed up in a single institute
phase II study to assess tolerability and efﬁcacy of
extended adjuvant metronomic capecitabine.
Patient characteristics
Median age was 50 years ranging from 27 to 67 years,
and 58.5% of patients were postmenopausal, while
92.5% of the enrolled patients presented at stages II
and III (Table 1).
Toxicity assessment
Toxicity was evaluated according to the National
Cancer Institute’s (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.03.
Generally, metronomic capecitabine was well toler-
ated with no major adverse effects. Adverse effects
consisted of grade 1 palmar-plantar erythrodysesthe-
sia, vomiting and/or diarrhea.
Only 13 patients (31.7%) developed grade 1 hand
and foot syndrome, ﬁve patients (12.2%) developed
grade 1 diarrhea, and two patients (4.9%) developed
grade 1 vomiting. No hematological, hepatic or renal
toxicities were reported.
No signiﬁcant correlation was found between the
development of side effects and presence of any
comorbid conditions (Table 2).
Using independent t-test P value 0.06, borderline
signiﬁcance was found between age and hand-foot
syndrome development. There was no signiﬁcant cor-
relation between age and development of diarrhea and
vomiting (P value 0.536. and 0.880, respectively).
Disease-Free Survival (DFS) analysis
The estimated median follow-up duration was
34 months. The estimated mean DFS was
42.4 months (95% CI, 39.02–45.79), while the med-
ian DFS was not reached (Figure 1).Estimated mean overall survival was 44.34 months
(95% CI 41.9–46.9) (Figure 2)Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
Figure 1. The Kaplan–Meier of disease-free survival (DFS) in the 41 eligible patients with triple-negative breast cancer who were treated with
extended adjuvant metronomic capecitabine for six months after six cycles of FEC100. Mean DFS was 42.4 months (95% CI: 39.02–45.79).
Figure 2. The Kaplan–Meier of overall survival (OS) in the 41 eligible patients with triple-negative breast cancer who were treated with extended
adjuvant metronomic capecitabine for six months after six cycles of FEC100. Estimated mean overall survival was 44.34 months (95% CI 41.9–46.9).
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Treatment options of TNBC are limited as these
tumors are naturally resistant to existing targeted
therapies by absence of estrogen receptors (ER), pro-
gesterone receptors (PR) and lack of overexpression
of HER2. However, TNBC is responsive to chemo-
therapy, and improvements in chemotherapy are likely
to preferentially beneﬁt this subtype of breast carci-
noma because of rapid proliferation rates and defects
in DNA repair.9
Regarding TNBC and its impact on the clinical
behavior of the disease, incidence, timing, and sites
of relapse, many randomized trials indicate that the
prognostic effect of TNBC is poor and is independent
of high grade, nodal status, tumor size, and treatment.10Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015Metronomic chemotherapy has attracted renewed
interest over the past few years, in particular because
of a possible positive association with molecular tar-
geted agents. It acts through stimulation of the
immune system and anti-angiogenic action.11
Several ongoing trials address the intensiﬁcation of
adjuvant chemotherapy in TNBC patients, either
through integration of novel agents into the adjuvant
setting such as platinums, capecitabine, ixabepilone or
bevacizumab, or through introduction of maintenance
therapy such as capecitabine (CIBOMA and
SYSUCC-001) or bevacizumab (BEATRICE Study).
CIBOMA 2004-01/GEICAM 2003-11 is a multi-
center, open-label, randomized phase III trial evaluat-
ing the efﬁcacy of maintenance treatment with
capecitabine in operable TNBC patients with25
26
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node-positive (or node-negative with tumor diameter
1 cm) who have received standard anthracycline
and/or taxane-containing chemotherapy. They were
randomized to receive eight cycles of capecitabine
(1000 mg/m2 bid, d1–14 q21d) (Arm A) or observa-
tion (Arm B). The primary endpoint is disease-free
survival.12
The ﬁrst safety data from the randomized phase
III trial (CIBOMA 2004-01/GEICAM 2003-11)
published by Lluch et al. in the 2010 San Antonio
Cancer Symposium revealed that the safety proﬁle
of adjuvant capecitabine as maintenance therapy was
consistent with its known toxicity proﬁle. More than
75% of patients were able to continue their treatment
as planned with approximately 15% of patients dis-
continuing due to toxicity or withdrawal. Grade 3
or 4 adverse effects were higher in maintenance cape-
citabine, hand-foot syndrome 17.4%, diarrhea 2.9%,
vomiting 1.0%, and elevated bilirubin 1.0%.13
Preliminary safety analyses on 405 patients
reported seven serious adverse events related to cape-
citabine treatment, including hospitalization for
grades 2–4 diarrhea, grade 2 thoracic pain, grade 2
arrhythmia, coronary vasospasm, and chest pain.13
In accordance with these data, our study showed
that extended adjuvant metronomic capecitabine was
well tolerated, with no severe or life threatening
adverse effects at all. Adverse effects were grade 1 pal-
mar-plantar erythrodysesthesia, vomiting and/or diar-
rhea. Only 13 patients (31.7%) developed grade 1
hand and foot syndrome, ﬁve patients (12.2%) devel-
oped grade 1 diarrhea and two patients (4.9%) devel-
oped grade 1 vomiting. There were no grade 3 or 4
toxicities or any hematological or hepatic toxicity.
Therefore, in comparison with the CIBOMA safety
proﬁle, the adverse effects in our study were much
lower due to the lower dose of capecitabine we used.
The effect of lower dose capecitabine on DFS is
needed for evaluation in a larger phase III study.
SYSUCC-001 is an open-label, randomized phase
III trial evaluating the efﬁcacy of adjuvant capecita-
bine metronomic chemotherapy to TNBC. In this
study, which is still recruiting participants, patients
with early TNBC are randomized to treatment with
standard adjuvant chemotherapy alone or standard
adjuvant chemotherapy followed by one year of cape-
citabine (Xeloda) metronomic therapy 650 mg/m2
twice every day. No published data are yet available.14
In our study, all patients received six cycles of
FEC100, unlike both CIBOMA and SYSUCC-001,
where patients received standard chemotherapy that
was anthracycline based or anthracycline/taxane
based. We aimed to give the patient uniform adjuvantchemotherapy for better assessment of the efﬁcacy of
metronomic capecitabine as well as provide patients
some ﬁnancial reprieve. Also in this study, and unlike
both CIBOMA and SYSUCC-001, patients with T4
and N3 were not excluded.
In another effort to evaluate the beneﬁt of mainte-
nance treatment for TNBC patients, the BEATRICE
study enrolled 1290 patients to receive chemotherapy
alone and 1301 to receive bevacizumab plus chemo-
therapy. At the time of the analysis for invasive dis-
ease-free survival (IDFS), median follow-up was
31.5 months (IQR 25.6–36.8) in the chemotherapy-
alone group and 32.0 months (27.5–36.9) in the bev-
acizumab group.
The three-year IDFS was 82.7% (95% CI 80.5–
85.0) with chemotherapy alone and 83.7% (81.4–
86.0) with bevacizumab and chemotherapy. After
200 deaths, no difference in overall survival was noted
between the groups (HR 0.84, 95% CI 0.64–1.12;
p = 0.23). Use of bevacizumab versus chemotherapy
alone was associated with increased incidences of
grade 3 or worse hypertension (154 patients [12%]
vs eight patients [1%]), severe cardiac events occurring
at any point during the 18-month safety reporting
period (19 [1%] vs two [<0Æ5%]), and treatment dis-
continuation (bevacizumab, chemotherapy, or both;
256 [20%] vs 30 [2%]).15
In light of these data, the use of metronomic cape-
citabine may gain more interest due to its low toxicity
proﬁle and its lower price tag.
In our study, only six (15%) relapse events
occurred. One of them (2.4%) was locoregional
relapse while the other ﬁve (12.6%) were disseminated
bone, lung, and liver metastasis. The incidence of both
local and distant relapses in our study was therefore
lower in comparison to the previously published data,
but a larger sample and longer follow-up is required
for better and more mature results. Also, due to the
small number of relapses, the pattern of relapse could
not be determined.
El-Arab et al. studied the clinical efﬁcacy and tol-
erability of low dose capecitabine (500 mg twice daily)
together with oral cyclophosphamide 50 mg once
daily in 60 patients with metastatic breast cancer.
The overall regimen was well tolerated. Palmar–plan-
tar erythrodysesthesia was the most common side
effect (grades 1 and 2 in 36.7% of cases). Leucopenia
(grades 1 and 2) was the most frequent hematological
toxicity and was observed in 17% of patients; nausea
and vomiting (grades 1 and 2) in 28.3% of patients;
while diarrhea (grades 1 and 2) in 20% of patients,
and grade 3 elevation of serum transaminases was
reported in 8% of patients.16Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
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In our study, palmar–plantar erythrodysesthesia
was the most common side effect, although there were
no grades 3 or 4 in either study. Vomiting in their
study was much higher at 28.3% in comparison to
4.9% in our study. This may be due to effect of che-
motherapy (CTX) in their study. Diarrhea in our
study was 12.2% lower in comparison to 20% in the
study by El-Arab et al. These differences could be
explained by the addition of CTX to Xeloda in their
study as well as the fact that their study was con-
ducted on metastatic patients, including those with
liver metastasis, and on patients who were heavily
pretreated.16
In another study by Fedele et al. which evaluated
the efﬁcacy and safety of low-dose metronomic che-
motherapy with capecitabine in heavily pretreated
patients with metastatic breast cancer, 60 patients
received continuous metronomic capecitabine mono-
therapy (1500 mg once a day). Hematologic toxicity
was infrequent and mild. Hand-foot syndrome
(10%) and diarrhea (7%) were the most commonHematol Oncol Stem Cell Ther 8(1) First Quarter 2015adverse effects; vomiting occurred in 2%, and all tox-
icities were less than grade 3. There were only three
cases of grade 3 toxicity, all involving hand-foot syn-
drome.17 These results were similar to ours as all tox-
icities were grade 1 and there were no hematological
or hepatic toxicities.CONCLUSION
Extended adjuvant metronomic capecitabine is well
tolerated with good patient compliance. Due to our
small sample size, these results need to be compared
in a study with a control arm, a larger sample as well
as longer follow-up. The need for higher doses of
capecitabine can be evaluated when the results of cur-
rent ongoing trials are available.CONFLICT OF INTEREST
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